Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| NanoViricides Inc. | NV-CoV-2 (NV-387) | RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infection | Phase 2 | Trial Planned | Oral | Antiviral |
| NanoViricides Inc. | NV-387 - (Virus Clade Ia and Ib) | Monkeypox Vaccine | Phase 2a | Trial Planned | Intranasal | N/A |
| Nasus Pharma Ltd. | NS002 | Anaphylaxis | Phase 2 | Ongoing | Intravenous | N/A |
| Natera Inc. | IBRANCE (palbociclib) - (PALLAS) | Early stage breast cancer | Phase 3 | Data Released | Oral | Oncology |
| Natera Inc. | Signatera test - (DECIPHER ) ('702 Study) | Stage 3 colorectal cancer | Phase 3 | Data Released | Not applicable | Oncology |
| Natera Inc. | Datopotamab deruxtecan (Dato) plus durvalumab (Durva) - (I-SPY2.2) | Breast cancer | Phase 2 | Data Released | Intravenous | Oncology |
| Natera Inc. | Giredestrant - (MiRaDoR) | Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer | Phase 2 | Ongoing | Oral | Oncology |
| Natera Inc. | Anti-HER2 targeted therapy (HEROES) | Metastatic HER2+ Breast Cancer | Phase 2 | Enrollment Initiation | Intravenous | Oncology |
